MTAP, the Myozyme® (alglucosidase alfa) Temporary Access Program, is a clinical program to provide access to Myozyme produced by a larger scale manufacturing process for a limited time until this manufacturing scale is approved by the FDA.  Patients enrolled in MTAP will be provided Myozyme at no cost during the course of the program.  The goals of MTAP are two-fold:  (a) to minimize any potential disruption in the treatment of patients already on therapy; and (b) to ensure that Myozyme is available for new patients who are in the most urgent clinical need.

Download complete article